Palvella Therapeutics PVLA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.07M+42.7% | $520K+85.1% | $628K+236% | $690K+902% | $752K+774% | ||
| $9.33M+129% | $7.12M+180% | $6.53M+105% | $5.12M+255% | $4.07M+314% | ||
| $5.52M+45.4% | $4.18M+129% | $3.65M+94.1% | $4.13M+182% | $3.8M+390% | ||
| $14.86M+88.7% | $11.3M+159% | $10.18M+101% | $9.25M+218% | $7.87M+347% | ||
| -$14.86M-88.7% | -$11.3M-159% | -$10.18M-101% | -$9.25M-218% | -$7.87M-347% | ||
| -$32K-114% | —— | $34K+270% | $561K+777% | $224K— | ||
| -$15.77M-92.6% | -$12.71M-222% | -$11.35M-67.5% | -$9.47M-127% | -$8.19M-223% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$15.77M-92.6% | -$12.71M-222% | -$11.35M-67.5% | -$9.47M-127% | -$8.19M-223% | ||
| -$1.20-62.2% | -$1.08— | -$1.03+73.9% | -$0.86+65.2% | -$0.74+51.9% | ||
| -$14.86M-88.7% | -$11.3M-159% | -$10.18M-101% | -$9.25M-218% | -$7.87M-347% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Palvella Therapeutics's revenue?
- Palvella Therapeutics (PVLA) generated $40.9M in revenue over the trailing twelve months, up 142.9% year over year.
- Is Palvella Therapeutics profitable?
- Palvella Therapeutics is not currently profitable: it reported a net loss of $49.3M over the trailing twelve months, a 71.7% net margin.
- What is Palvella Therapeutics's earnings per share?
- Palvella Therapeutics's diluted EPS over the trailing twelve months is $-4.17.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
